Huntington Disease
Conditions
Keywords
ubiquinol, coenzyme Q10, Huntington disease
Brief summary
The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals. Most studies of CoQ have looked at only one formulation of CoQ (ubiquinone) in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ (ubiquinone) to a different formulation (ubiquinol) have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.
Interventions
DIETARY_SUPPLEMENTubiquinol
up to 600 mg per day, oral capsules for 8 weeks
Sponsors
Kaneka Corporation
University of Rochester
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have manifest Huntington disease * Be 18 years of age or older * Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit * Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit
Exclusion criteria
* Have a history of intolerability of sensitivity to CoQ * Have an unstable medical or psychiatric illness * Be pregnant or breastfeeding; women of childbearing age must use reliable contraception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| serum coenzyme Q10 levels | 8 weeks |
Countries
United States
Outcome results
None listed